Pathstone Holdings LLC Boosts Stock Holdings in Thermo Fisher Scientific Inc. (NYSE:TMO)

Pathstone Holdings LLC lifted its stake in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 12.5% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 75,556 shares of the medical research company's stock after purchasing an additional 8,408 shares during the period. Pathstone Holdings LLC's holdings in Thermo Fisher Scientific were worth $46,739,000 at the end of the most recent quarter.

Several other institutional investors have also recently bought and sold shares of TMO. Peterson Financial Group Inc. acquired a new position in Thermo Fisher Scientific during the 3rd quarter valued at about $27,000. Signature Resources Capital Management LLC raised its holdings in Thermo Fisher Scientific by 318.2% during the 2nd quarter. Signature Resources Capital Management LLC now owns 46 shares of the medical research company's stock worth $25,000 after buying an additional 35 shares during the period. New Millennium Group LLC bought a new stake in Thermo Fisher Scientific in the 2nd quarter valued at $29,000. Stephens Consulting LLC boosted its stake in Thermo Fisher Scientific by 116.0% in the 2nd quarter. Stephens Consulting LLC now owns 54 shares of the medical research company's stock worth $30,000 after purchasing an additional 29 shares during the period. Finally, Bank & Trust Co acquired a new stake in shares of Thermo Fisher Scientific in the 2nd quarter valued at about $33,000. Institutional investors own 89.23% of the company's stock.

Analysts Set New Price Targets

A number of brokerages recently issued reports on TMO. TD Cowen lifted their target price on Thermo Fisher Scientific from $656.00 to $686.00 in a research report on Tuesday, October 22nd. Stifel Nicolaus cut their price target on shares of Thermo Fisher Scientific from $680.00 to $665.00 and set a "buy" rating on the stock in a research report on Thursday, October 24th. Redburn Atlantic assumed coverage on Thermo Fisher Scientific in a research report on Monday, October 14th. They issued a "buy" rating and a $680.00 target price on the stock. Raymond James increased their price target on Thermo Fisher Scientific from $650.00 to $660.00 and gave the company an "outperform" rating in a research report on Thursday, July 25th. Finally, Robert W. Baird lowered their price target on Thermo Fisher Scientific from $632.00 to $622.00 and set an "outperform" rating on the stock in a research report on Thursday, October 24th. Four investment analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, Thermo Fisher Scientific presently has an average rating of "Moderate Buy" and a consensus price target of $649.33.

Insider Activity at Thermo Fisher Scientific

In other news, CEO Marc N. Casper sold 10,000 shares of the business's stock in a transaction dated Monday, October 28th. The stock was sold at an average price of $554.29, for a total value of $5,542,900.00. Following the transaction, the chief executive officer now directly owns 121,192 shares of the company's stock, valued at $67,175,513.68. The trade was a 7.62 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, SVP Michael A. Boxer sold 2,000 shares of the company's stock in a transaction that occurred on Friday, October 25th. The stock was sold at an average price of $560.16, for a total value of $1,120,320.00. Following the transaction, the senior vice president now directly owns 12,736 shares in the company, valued at approximately $7,134,197.76. This trade represents a 13.57 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 37,150 shares of company stock worth $20,651,865 over the last three months. Company insiders own 0.34% of the company's stock.

Thermo Fisher Scientific Price Performance

Shares of TMO traded up $7.85 during midday trading on Tuesday, hitting $509.15. The company's stock had a trading volume of 3,625,174 shares, compared to its average volume of 1,491,361. The company has a quick ratio of 1.26, a current ratio of 1.63 and a debt-to-equity ratio of 0.64. Thermo Fisher Scientific Inc. has a one year low of $465.90 and a one year high of $627.88. The stock has a market capitalization of $194.75 billion, a price-to-earnings ratio of 31.92, a price-to-earnings-growth ratio of 3.39 and a beta of 0.79. The company's fifty day simple moving average is $581.75 and its two-hundred day simple moving average is $581.46.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last announced its quarterly earnings results on Wednesday, October 23rd. The medical research company reported $5.28 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.25 by $0.03. The company had revenue of $10.60 billion during the quarter, compared to the consensus estimate of $10.63 billion. Thermo Fisher Scientific had a net margin of 14.48% and a return on equity of 17.49%. The company's revenue for the quarter was up .2% compared to the same quarter last year. During the same period in the prior year, the business earned $5.69 earnings per share. As a group, equities analysts expect that Thermo Fisher Scientific Inc. will post 21.67 earnings per share for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, January 15th. Stockholders of record on Friday, December 13th will be issued a dividend of $0.39 per share. The ex-dividend date of this dividend is Friday, December 13th. This represents a $1.56 dividend on an annualized basis and a dividend yield of 0.31%. Thermo Fisher Scientific's dividend payout ratio (DPR) is presently 9.78%.

Thermo Fisher Scientific announced that its Board of Directors has approved a share repurchase program on Friday, November 15th that authorizes the company to buyback $4.00 billion in shares. This buyback authorization authorizes the medical research company to purchase up to 2% of its shares through open market purchases. Shares buyback programs are often a sign that the company's board believes its stock is undervalued.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.